Syntiron’s pipeline of preclinical vaccine candidates demonstrates the unique strength of the iron-regulated protein vaccine platform for developing vaccines against diverse bacterial pathogens, including Gram-negative and Gram-positive bacteria. The E. coli and Staphylococcus aureus vaccine development projects are both currently active and are partially supported by the National Institutes of Health through Small Business Innovation Research grants to Syntiron. The Staphylococcus aureus and Biodefense vaccines (Y. pestis, B. anthracis and B. pseudomallei) have also previously been partnered with private and public partners including NIH, Sanofi Pasteur and the Defense Threat Reduction Agency. Contact us if you are interested in partnering with Syntiron for commercial development of one of our existing pipeline vaccine candidates or if you are interested in a bacterial vaccine candidate that is not listed here. With our platform, expertise and extensive intellectual property portfolio, we can jump start your vaccine development pipeline.